

The logo for Alpha, featuring the word "Alpha" in a white, sans-serif font followed by a circular icon containing a stylized human figure. The background is a vibrant teal with abstract, glowing molecular or cellular structures.

Olainfarm to Become *Alpha*


Information for our cooperation partners

Dear cooperation partners,

We are proud to announce that we have taken another courageous and powerful step in our development by introducing a new visual identity, brand and name. We are doing this to achieve our goal of successfully and effectively becoming one of the leading pharmaceutical companies in Europe, providing ever more accessible pharmaceutical solutions. These changes encompass a broader portfolio of drugs in new therapeutic groups, focusing on the significant expansion of activities in a range of markets in Western countries. This is why *Olainfarm* is transforming into *Alpha*! The changes are related not only to our brand, but also to our legal name, which in future will be Joint Stock Company *Alpha*.

What is *Alpha*?

The name *Alpha* indicates our local origins (*Olaine*) and the field that we represent (*pharmaceuticals*). The name preserves the essence of our history, giving it a new contemporary, harmonious and international sound. The new logo symbolizes our main value – the person, whereas our new motto, *Within Reach*, symbolizes our resolve to ensure high quality healthcare and access to medicine for anybody who needs it.

The Alpha logo, consisting of the word "Alpha" and a circular icon with a stylized human figure, set against a teal background.

Within Reach

Why *Olpha*?

A change in brand is quite a rare and courageous step in pharmacy. We have decided to take this step because *Olpha* is ready to expand into new markets throughout the world, with a special emphasis on Europe. Currently, more than 50 new patent-free pharmaceuticals have been approved among the company's portfolio of products. Registration of these has commenced commensurate with the market situation, adapting our medical products for markets in Western countries and the rest of the world. Already, 31 pharmaceuticals have been submitted for registration in the fields of cardiology, neurology, urology, oncology, and for the treatment of diabetes, infections or allergies.



The first commercialization of several products is planned to begin this year, as soon as all regulatory requirements have been fulfilled, including in Latvia as well. Meanwhile, there are about 100 new products in various phases of the development process.

Olpha's strategic plan leading up to 2030 envisages even greater concentration on research and development, adding newly developed forms of drugs and active pharmaceutical agents to our portfolio of products each year. Significant international expansion into new markets in various stages – in Western Europe, the Middle East, Northern Africa and North America - is also planned within it. The company also intends to work more actively on its internal and collaboration culture, facilitating an indefatigable spirit of entrepreneurship, and on a result-focused attitude and care for people at all levels of cooperation.

How do you orient yourself within these changes?

We will introduce and deliver information updates, including brand materials, product catalogues and digital resources in a thoughtful and gradual way, although there will not be many changes to our everyday work and collaboration. We have also developed a new home page *olpha.eu*, and the domain in our employees' emails will also be changed to *olpha.eu*.



We will continue to collaborate successfully

Our individual cooperation will remain the same, even though there will be changes to our visual appearance and goals for reaching target markets. Existing contracts will continue as agreed, and our collaboration will continue with our cooperation partners according to the terms of these contracts.

The only changes to our company details are with respect our name, which has now been officially registered with the Republic of Latvia's Register of Enterprises. Additionally, please note that our e-mail domain will gradually be changed to *olpha.eu*. All other contact information remains the same. We kindly invite you to update your records to reflect our new company name where possible, particularly in invoices. We understand that this transition may take some time and appreciate your cooperation.

Our updated company details are as follows:

Joint Stock Company Olpha

Unified Registration No. 40003007246

VAT Payer No. LV40003007246

Legal Adress: Rūpnīcu Street 5, Olaine, Olaine District, Republic of Latvia, LV-2114

Bank: AS "SEB banka"

SWIFT: UNLALV2X

EUR account: LV94UNLA0050003735211

USD account: LV37UNLA0050003735170

Should you have any questions, please feel free to reach out us at olpha@olpha.eu.

We are committed to develop a more pleasant and productive collaboration with you in the future and sincerely appreciate your trust and our mutual work up until now. We are here and always accessible to you.

Wishing you a successful collaboration,

Juris Bundulis

Chairman of the Board at *Olpha*